Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$723.57 USD

723.57
514,425

-8.63 (-1.18%)

Updated Apr 25, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 16% (211 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Eli Lilly (LLY) Price Targets

Average Price Target Highest Price Target Lowest Price Target Upside to Average Price Target
$774.48 $950.00 $560.00 5.77%

Price Target

Based on short-term price targets offered by 21 analysts, the average price target for Eli Lilly comes to $774.48. The forecasts range from a low of $560.00 to a high of $950.00. The average price target represents an increase of 5.77% from the last closing price of $732.20.

Analyst Price Targets (21)

Last Close 732.20
Average 774.48 5.77% Upside Low 560.00 -23.52% Downside High 950.00 29.75% Upside

Broker Rating

Eli Lilly currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 22 recommendations.

Of the 22 recommendations deriving the current ABR, 19 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 86.36% and 4.55% of all recommendations. A month ago, Strong Buy made up 86.36%, while Buy represented 4.55%.

Broker Rating Breakdown

Broker Rating Visualization

Brokerage Recommendations

Today 1 Week Ago 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 19 19 19 19 19
Buy 1 1 1 1 1
Hold 2 2 2 2 2
Sell 0 0 0 0 0
Strong Sell 0 0 0 0 0
ABR 1.20 1.20 1.20 1.20 1.20

1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.

2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.

Analyst Upgrades/Downgrades

Date Brokerage Firm Analyst Previous Current
4/12/2024 SVB Securities David Risinger Strong Buy Strong Buy
4/2/2024 Guggenheim Securities Seamus Fernandez Strong Buy Strong Buy
4/1/2024 Cantor Fitzgerald & Co Louise Chen Strong Buy Strong Buy
3/15/2024 Truist Securities Robyn Karnauskas Strong Buy Strong Buy
2/7/2024 BMO Capital Markets Evan Seigerman Strong Buy Strong Buy
1/3/2024 Argus Research Corp. David A Toung Strong Buy Strong Buy
12/21/2023 Daiwa America Narumi Nakagiri Not Available Strong Buy
11/8/2023 Not Identified Not Identified Strong Buy Strong Buy
9/4/2023 Berenberg Bank Kerry Holford Strong Buy Strong Buy

1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.

2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.

Average Brokerage Rating

Current ABR

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for most of the leading investment web sties. The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock.

ABR vs Zacks Rank

 1.20
ABR (Last week) 1.20
# of Recs in ABR 22
Average Target Price $774.48
LT Growth Rate 36.60%
Industry Large Cap Pharmaceuticals
Industry Rank by ABR 211 of 252
Current Quarter EPS Est: 2.53